OptiNose's Norwegian affiliate has received a 12.3 million Norwegian krones ($2.1 million) award from the Research Council of Norway to fund its "nose-to-brain" research for the treatment of autism spectrum disorders. OptiNose's research is looking at the company's bi-directional dry powder delivery technology to deliver nasal oxytocin for the treatment of autism. This delivery system gets the drug deep into the nasal regions and into the brain via the olfactory nerve. OptiNose originated in Norway but moved its operations to the U.S. to improve its funding options. Press release